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Abstract 
 Nanotechnology aims to manipulate characteristics of matter at atomic scale in order 
to improve drug delivery systems. The purpose of this extended essay is to investigate how 
surface properties of nanoparticles and drug delivery sytems of these molecules are affected 
of the concentration of the stabilizer, used during the preparation. The research question is 
"How does changing the concentration of the stabilizer affect the surface properties of the 
nanoparticles and the drug delivery systems that are formed with the nanoparticles of 2% 
PLGA (poly(lactic-co-glycolic acid)) and the stabilizer concentrations of 1%, 2%, 3%, 4% and 
5% PVA (polyvinyl alcohol), by solvent evaporation method?".  
 The hypothesis states that there will be significant difference between the means of 
sizes and zeta potentials of nanoparticles that are produced with varying PVA 
concentrations. Thus, it will be concluded that drug delivery systems will have variety, as 
well.  
 So as to verify the hypothesis, nanoparticles of PLGA are going to be prepared by 
solvent evaporation method where PVA concentration is going to be the independent 
variable. Solutions containing PLGA and PVA are mixed and the solvent is evaporated by 
stirring at high rates in this method. Then, the particles are analysed with a software 
programme and data of size and zeta potential are compared. 
 The results illustrated that mean size and zeta potential values of varying 
concentrations showed significant differences. Therefore, the biocompatibilities of 
nanoparticles can be altered by changing the stabilizer concentration. 
Word count: 238 
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Introduction 
 I have been interested in nanotechnology and especially nanomedicine since I first 
saw my brother's scientific journals of The Scientific and Technological Research Council of 
Turkey, "Bilim ve Teknik", where I read about this new technology. So, I decided to visit a 
pharmaceutics laboratory and asked a pharmacist who is one of my mother's friends. After 
my visit to the lab, I started doing research on the topic and learned that nanotechnology 
promises a wide range of reforms for drug delivery. Thus, I decided doing my research on 
nanomedicine and especially the use of nanomedicine on drug delivery.  
 After doing some investigation on the topic and reading articles such as 
"Nanotechnology for the biologist"1, I found out that nanotechnology includes all research 
done with the purpose of changing the characteristics of a substance on an atomic scale. On 
the other hand, nanomedicine deals with the medical applications of nanotechnology such as 
diagnosing and treating diseases with the help of nanoparticles. Another aim of 
nanomedicine is the development of drug delivery systems based on nanoparticles.  
 I learned the importance of drug delivery systems of nanoparticles is that they can 
escape the reticuloendothelial system (RES), which is a part of the immune system and 
functions to remove foreign molecules from the body. The time period during which they can 
stay in the body is much longer than larger molecules since larger molecules are detected 
easier than nanoparticles. Additionally, it is worth noting that nanoparticles are able to 
interact with biomolecules on the cell surface because they have similar dimensions.1 
 Another advantage of nanoparticles in drug delivery that caught my attention was the 
fact that their surface properties can be altered to have desired characteristics as mentioned 
in "Nanoparticles – A Review"2, "Particle size and surface characteristics of nanoparticles 
can be easily manipulated..". These desired properties may include the surface charge of the 
particle, its size or its solubility in different solvents. Surface charge of a nanoparticle is 
characterized by its zeta potential, where zeta potential indicates the stability of the particle 
and shows its electrical potential. It is mostly influenced by the composition of the 
nanoparticle and the medium in which it is dispersed. Nanoparticles having a zeta potential 
value above (+/-) 30mV have shown to be stable in suspension, as the surface charge 
prevents aggregation.2 After reading this article, by VJ Mohanraj2, about drug delivery 
systems and nanoparticles, I realised that it is important to have particles that are stable 
because if the particles aggregate, they will not function properly. As zeta potential 
demonstrates the degree of repulsion between similarly charged particles; a high zeta 
potential means that the molecules can resist the repulsion forces; thus can resist 
aggregation. 
 In "Biodegradable polymeric nanoparticles based drug delivery systems"3, the article I 
have examined, I saw that there are many polymers used in drug delivery systems such as 
PLGA (poly(lactic-co-glycolic acid)), PEG (polyethylene glycol), gelatin and chitosan. PLGA 
is one of the most commonly used polymers for the preparation of nanoparticles in 
pharmaceutics. It is an approved polymer being studied for many years as a suitable drug 
delivery material due to its biocompatibility, biodegradability and non-toxicity.4 By the usage 
of this polymer, surface charge, solubility and some other properties of the drug molecule 
can be changed. The reasons that have affected my decision on polymer choice being PLGA 
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were that it is not harmful to human body and I am allowed to use this polymer, but not 
others, because I am a non-professional at the area. 
 To obtain a nanomolecule of PLGA, I had to choose a method suitable for the 
characteristics of the polymer and while deciding, had to consider the fact that it should be a 
method I can use. After some research, I found that solvent evaporation method is the most 
convenient one in these conditions. In this method, the polymer should be solved with an 
organic solvent and then added into the aqueous phase with stabilizer. In this experiment, 
the organic solvent is acetone whereas PVA (polyvinyl alcohol), a water-soluble synthetic 
polymer, is the stabilizer which are picked from the article "Formulation and characterization 
of biodegradable nanoparticles for intravascular local drug delivery"5. It is stated in the article 
"Nanoparticles – A Review"2 that particle size is influenced by the concentration of the 
stabilizer. Stabilizer is a compound that decreases the surface tension and avoids the 
aggregation of the nanoparticles. 
 With all these information, the topic of my research will be comparing the 
characteristics such as size and zeta potential of blank PLGA nanoparticles which are 
prepared with different concentrations of water phase (PVA solution) and commenting on 
their differences in drug delivery systems. Size and zeta potential values are used in the 
comparison because they indicate the functionality of a nanoparticle as stated earlier. There 
are many studies with the purpose of developing nanotechnological drugs to overcome 
barriers in body such as blood-brain barrier (BBB) and to cure diseases in easier ways by 
altering the characteristics of the devices used. My research question in this study is "How 
does changing the concentration of the stabilizer affect the surface properties of the 
nanoparticles and the drug delivery systems that are formed with the nanoparticles of 2% 
PLGA (poly(lactic-co-glycolic acid)) and the stabilizer concentrations of 1%, 2%, 3%, 4% and 
5% PVA (polyvinyl alcohol), by solvent evaporation method?". 
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Hypothesis 
 Nanotechnology is the study of particles on the atomic level, generally dealing with 
molecules having a size between 1-100 nanometers. The main purpose is to manipulate the 
surface properties of the substance and to obtain particles with desired characteristics to use 
in drug delivery. 
PLGA is a copolymer that has biocompatibility and biodegradability properties making 
it used in drug delivery systems. Although its monomers (lactic acid and glycolic acid) have 
poor solubilities, PLGA can be dissolved by a wide range of common solvents.4 
The characteristics of nanoparticles can be altered easily by many factors such as the 
type and concentration of both polymer and stabilizer, stirring speed and the preparation 
method as stated in the article "Nanoparticles - A Review"2.  With reference to the study "The 
influence of technological parameters on the physiochemical properties of blank PLGA 
nanoparticle"3, where it is shown experimentally that the factors listed above affect the 
properties of nanoparticles, it was hypothesized that "There is a significant difference 
between the biocompatibilities and drug delivery properties due to the different sizes and 
zeta potentials of nanoparticles that are prepared with 2% PLGA (poly(lactic-co-glycolic 
acid)) and varying concentrations (1%, 2%, 3%, 4% and 5%) of PVA (polyvinyl alcohol) by 
solvent evaporation method." 
The characteristics that will be compared in this research are size and zeta-potential 
values of blank PLGA nanoparticles. 
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Method Development and Planning 
 In order to observe how the concentration of the stabilizer affects the nanoparticle’s 
size, zeta potential values and the biocompatibility of the molecule, I had to conduct an 
experiment with the chemicals that are most suitable. With this aim in mind, I started 
searching for articles about nanoparticle preparation. From these articles such as "Controlled 
release systems and polymers used in these systems"7, I learned that various chemicals can 
be used to produce nanoparticles to work in the best way by using different methods. After 
gaining some information on the preparation methods, I talked with a pharmacist in order to 
decide which chemicals to use and which method to perform during my experiment.  
As a non-professional at this area, I had to find chemicals that are not harmful for 
human body and are allowed for student experiments. Due to this reason, my choices of 
chemicals were PLGA, PVA and acetone. In this experiment, independent variable was 
decided to be the concentration of PVA and dependent variable to be the characteristics of 
the PLGA nanoparticles where acetone was used as the solvent.  
 I had realized that the preparation method is usually determined according to the 
desired properties of the final product and the properties of the chemicals being used. The 
polymer used in the experiment was PLGA, a hydrophobic molecule. According to "Polymer 
nanoparticles: Preparation techniques and size-control parameters"8, "solvent evaporation 
method" is the most appropriate and common one with PLGA. Thus, I determined my 
method to be solvent evaporation, which is preferred when the nanoparticle is being obtained 
from an early prepared polymer. After deciding on the polymer and the method, I had to 
choose the stabilizer and the solvent; both of which have important functions in the 
production of the nanoparticles. Two different organic solvents had been used in solvent 
evaporation method for years, one of which was toxic. So that, acetone, having much less 
toxicity, became the solvent of my experiment. The last chemical to be determined was the 
stabilizer and in this case there weren't any other options than PVA because of my polymer. 
 Solvent evaporation method is the name given to the process of preparing a 
nanoparticle from a present polymer. In this method, solution containing the polymer and the 
stabilizer are mixed and the solvent is evaporated by stirring it at high rates or increasing the 
temperature.9 Since the temperature change can affect the characteristics of the 
nanoparticles, only stirring will be used in this research and temperature will be constant. 
 Another important thing in developing the method is controlling all the variables that 
might have an effect on the results. It was stated that particle size is influenced by the type of 
the stabilizer, homogenizer speed, temperature and polymer concentration.2 So as to control 
these variables, same source of chemicals are used in all trials and the type of stabilizer is 
always PVA. Similarly, all of the devices, such as homogenizer and magnetic stirrer are 
identical with fixed values of speed for varying concentrations of PVA. For control of 
temperature, heater of the magnetic stirrer is turned off at all times and the mixtures are kept 
in the same room, being exposed to identical conditions, whereas during centrifuge, the 
device is adjusted to 4°C. Moreover, PLGA is used with a constant concentration of 2% 
throughout the experiment. 
 Purities of the mixtures are protected by covering the containers with parafilm when 
they are not being used.  
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 Analysis of the nanoparticles can only be done with technological devices due to the 
fact that the molecules are too small for observation with naked eye. I didn't know how I 
could do the analysis hence, I asked a pharmacist to learn that there are machines and 
software programmes for this purpose. The data obtained from the software programme is 
going to be used in the comparison of nanoparticle characteristics -zeta potential and size- 
when concentration of the stabilizer is changing. 
 At the end of the experiment, photographs of the nanoparticles are going to be taken 
with Transmission Electron Microscopes (TEM) in TEM laboratories of METU, Turkey. These 
photographs are going to provide information about relative sizes of particles. 
 With a view to find chemicals and necessary devices, I asked for help from the 
pharmacists of Hacettepe University, Turkey. By providing me with a suitable laboratory, they 
gave me access to the centrifuge, homogenizer, magnetic stirrers, ultrapure water system, 
zeta-size analyzer and other tools that might be needed. Likewise, the chemicals (PVA, 
PLGA and acetone) are supplied by the university in necessary amounts.  
 In order to reduce error sources, the experiment has to be conducted very carefully, 
following the steps of the method and under the supervision of a professional. I performed 
my experiment after watching a professional following a similar method so as to avoid 
mistakes. By this way, I gained some experience and knowledge about what to do first and 
how to do it. Also, one of the pharmacists working at Hacettepe University observed my 
experiment and warned me when it was necessary. 
 I expect that the characteristics of nanoparticles which have varying stabilizer 
concentrations will be different from each other. 
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Materials 
100.00mL beaker (15 of them, glass) 
200.00mL beaker (5 of them, glass) 
10.00mL graduated cylinder (1 of them, glass) 
100.00mL graduated cylinder (1 of them, glass) 
1000.00mL graduated cylinder (1 of them, glass) 
Cuvette (5 of them, plastic) 
Pasteur pipette (3 of them, plastic) 
5.00mL pipette (2 of them, glass) 
10.00mL pipette (2 of them, glass) 
Pipette pump (1 of them) 
Spatula (1 of them) 
Stirring rod (1 of them, glass) 
Parafilm 
Magnetic stirrer (5 of them) 
Magnetic stir bar (5 of 3 cm long, 5 of 1 cm long) 
Electronic scale (1 of them) 
1.00mL syringe (5 of them) 
10.00mL syringe (5 of them) 
Homogenizer (1 of them) 
Centrifuge (1 of them) 
Centrifuge tube (5 of them, plastic) 
Ultrapure water (1000.00mL) 
Ultrapure water system 
Zeta-size analyzer (Zetasizer) 
PLGA -poly(lactic-co-glycolic acid) (1.000g) 
PVA -polyvinyl alcohol (7.500g) 
Acetone (50.00mL) 
Gloves 
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Method 
Part 1: Preparation of water phase (1%, 2%, 3%, 4% and 5% PVA solutions) 
1. Take 0.500g of PVA in a 100.00mL beaker for 1% PVA solution. 
2. Add 50.00mL of ultrapure water into the beaker. 
3. Add a 1cm long magnetic stir bar and place the beaker on the magnetic stirrer. Stir 
PVA and ultrapure water for 3-3.5 hours at 750rpm (rate per minute) until all PVA 
dissolves in water. Do not use the heater. 
4. Repeat steps 1-3 with 1.000g, 1.500g, 2.000g and 2.500g of PVA instead of 0.500g 
for 2%, 3%, 4% and 5% PVA solutions respectively. 
Part 2: Preparation of organic phase (2% PLGA solution) 
1. Take 0.200g of PLGA in a 100.00mL beaker. 
2. Add 10.00mL of acetone into the beaker. 
3. Add a 1cm long magnetic stir bar and place the beaker on the magnetic stirrer. Stir 
PLGA and acetone for 2 minutes at 750rpm until all PLGA dissolves in acetone. Do 
not use the heater. 
4. Repeat steps 1-3 with the same amount of chemicals for 4 more times. 
 Part 3: Preparation of nanoparticles 
1. Take 20.00mL of 1% PVA in a 300.00mL beaker. 
2. Take 10.00mL of 2% PLGA in a 50.00mL beaker. 
3. Add a 3cm long magnetic stir bar into the 300.00mL beaker that has 20.00mL of 1% 
PVA in it. Place the beaker on the magnetic stirrer at 750rpm. 
4. Get all of the 2% PLGA solution into a syringe. 
5. Quickly pour the organic phase into the water phase. Water phase should be stirred 
by the magnetic stirrer during the process. Do not use the heater. 
6. Stir the mixture for 2 minutes at constant temperature. 
7. Repeat the steps 1-6 with 2%, 3%, 4% and 5% PVA instead of 1% PVA solution. 
8. Remove the magnetic stir bar from the beaker. Stir the 1% PVA + 2% PLGA mixture 
with homogenizer at 11000rpm for 2 minutes. 
9. Repeat step 8 with 2% PVA + 2% PLGA, 3% PVA + 2% PLGA, 4% PVA + 2% PLGA 
and 5% PVA + 2% PLGA mixtures instead of 1% PVA + 2% PLGA mixture under the 
same conditions. 
10. Add 30.00mL of ultrapure water into each of the beakers. 
11. Place a 3 cm magnetic stir bar in each of the beakers. 
12. Cover the beakers with parafilm to protect from impurities that might enter during the 
stirring process. Open small holes with a needle on the parafilm in order to let the 
solvent evaporate. 
13. Place the beakers on the magnetic stirrers. Stir the mixtures for 20-22 hours at 
750rpm and constant temperature to evaporate the solvent. Do not use the heater. 
14. After solvent evaporation, remove magnetic stir bars and parafilm from the beakers. 
Pour the mixtures into centrifuge tubes and label each tube. 
15. By weighing the tubes with an electronic scale, equalize the masses of the tubes for 
proper centrifugation. 
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16. Place the first tube in the centrifuge and the other tube at its opposite hole. Total 
weight must be equal, and the system must be in equilibrium. 
17. Centrifuge the mixtures for 30 minutes at 13500rpm and 4.00°C. 
18. After centrifugation, remove supernatant from the tube. Keep the precipitate. 
19. Add 10.00mL ultrapure water into each of the centrifuge tubes. 
20. Get all the particles that are on the walls of the tube into the water by scratching the 
tube’s walls with a stirring rod. 
21. Repeat the steps 15-19 for removal of clearing water. This time, centrifuge for 10 
minutes instead of 30 minutes.  
22. Add 10.00mL of ultrapure water into each tube for dilution. 
Part 4: Analysis of nanoparticles 
1. With a 1.00mL syringe, fill a cuvette quickly with 1% PVA + 2% PLGA solution. There 
must not be any air bubbles in the cuvette. 
2. Place the cuvette inside the zeta-size analyzer. 
3. With the Zetasizer Software, measure the sizes and zeta potentials of the particles. 
4. Remove the cuvette and repeat the steps 1-3 with 5% PVA + 2% PLGA solution. 
Repeat the procedure for 4 more times. 
Notes: Always label the containers with concentration values. 
Wear gloves at all times for safety. 
Always cover the containers with parafilm. 
Material list is for one trial only. 
  
Mine Su Erturk 
D1129056 
11 
 
Data Collection and Processing 
  
T
a
b
le
 1
: 
s
h
o
w
s
 t
h
e
 s
iz
e
s
 a
n
d
 z
e
ta
 p
o
te
n
ti
a
ls
 o
f 
n
a
n
o
p
a
rt
ic
le
s
 w
it
h
 r
e
s
p
e
c
t 
to
 t
h
e
ir
 v
a
lu
e
s
 o
f 
P
V
A
 c
o
n
c
e
n
tr
a
ti
o
n
s
 w
h
e
re
 P
L
G
A
 c
o
n
c
e
n
tr
a
ti
o
n
 i
s
 2
%
; 
a
n
d
 t
h
e
 c
o
n
s
ta
n
t 
v
a
ri
a
b
le
s
: 
m
a
s
s
 o
f 
P
L
G
A
, 
v
o
lu
m
e
 o
f 
u
lt
ra
p
u
re
 w
a
te
r 
u
s
e
d
 t
o
 d
is
s
o
lv
e
 P
V
A
, 
d
u
ra
ti
o
n
 o
f 
m
a
g
n
e
ti
c
 s
ti
rr
in
g
 f
o
r 
d
is
s
o
lv
in
g
 P
V
A
, 
v
o
lu
m
e
 o
f 
a
c
e
to
n
e
 u
s
e
d
 t
o
 d
is
s
o
lv
e
 P
L
G
A
, 
d
u
ra
ti
o
n
 o
f 
m
a
g
n
e
ti
c
 s
ti
rr
in
g
 f
o
r 
d
is
s
o
lv
in
g
 P
L
G
A
, 
d
u
ra
ti
o
n
 o
f 
m
a
g
n
e
ti
c
 s
ti
rr
in
g
 t
o
 e
v
a
p
o
ra
te
 t
h
e
 s
o
lv
e
n
t,
 r
a
te
 o
f 
m
a
g
n
e
ti
c
 s
ti
rr
in
g
, 
d
u
ra
ti
o
n
 o
f 
fi
rs
t 
c
e
n
tr
if
u
g
e
, 
d
u
ra
ti
o
n
 o
f 
s
e
c
o
n
d
 c
e
n
tr
if
u
g
e
, 
ra
te
 o
f 
c
e
n
tr
if
u
g
e
, 
te
m
p
e
ra
tu
re
 d
u
ri
n
g
 c
e
n
tr
if
u
g
e
, 
d
u
ra
ti
o
n
 o
f 
h
o
m
o
g
e
n
iz
a
ti
o
n
, 
ra
te
 o
f 
h
o
m
o
g
e
n
iz
a
ti
o
n
. 
 
Mine Su Erturk 
D1129056 
12 
 
  
T
a
b
le
 
2
: 
s
h
o
w
s
 
m
e
a
n
, 
m
o
d
e
, 
m
e
d
ia
n
, 
s
ta
n
d
a
rd
 
d
e
v
ia
ti
o
n
, 
s
ta
n
d
a
rd
 
e
rr
o
r,
 
t,
 
9
5
%
 
c
o
n
fi
d
e
n
c
e
 
in
te
rv
a
l 
v
a
lu
e
s
 
fo
r 
th
e
 
d
a
ta
 
o
f 
s
iz
e
 
a
n
d
 
z
e
ta
 
p
o
te
n
ti
a
l 
o
f 
n
a
n
o
p
a
rt
ic
le
s
 w
it
h
 r
e
s
p
e
c
t 
to
 t
h
e
ir
 c
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
P
V
A
. 
Mine Su Erturk 
D1129056 
13 
 
 
Anova: Single Factor 
     
       SUMMARY 
     Groups Count Sum Average Variance 
  1% 5 791.9 158.38 0.372 
  2% 5 837.1 167.42 2.117 
  3% 5 852.8 170.56 2.023 
  4% 5 1076.3 215.26 6.773 
  5% 5 1122 224.4 0.125 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 18349.67 4 4587.417 2010.262 9.7E-26 2.866081 
Within Groups 45.64 20 2.282 
   
       Total 18395.31 24         
Table 3: Single factor Analysis of Variance (ANOVA) statistical calculation for all groups of sizes of nanoparticles. 
 
Anova: Single Factor 
     
       SUMMARY 
     Groups Count Sum Average Variance 
  1% 5 -32.55 -6.51 0.15455 
  2% 5 -68.7 -13.74 0.053 
  3% 5 -31.55 -6.31 0.0384 
  4% 5 -79.9 -15.98 0.087 
  5% 5 -41.24 -8.248 0.00447 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 392.4476 4 98.11189 1453.854 2.45E-24 2.866081 
Within Groups 1.34968 20 0.067484 
   
       Total 393.7973 24         
Table 4: Single factor Analysis of Variance (ANOVA) statistical calculation for all groups of zeta potential of 
nanoparticles. 
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Discussion 
 In this research, the aim was to observe the effect of the stabilizer concentration on 
the surface properties of nanoparticles that were prepared with 2% PLGA polymer and 
varying concentrations (1%, 2%, 3%, 4%, 5%) of PVA. The hypothesis was that there would 
be significant difference between the sizes and the zeta potentials of the particles due to their 
stabilizer concentrations, hence expected biocompatibilities of these molecules would be 
compared. 
 It was seen that the biggest molecule size belonged to the nanoparticles that were  
produced from 5% PVA while 4%, 3%, 2% and 1% concentrations followed decreasingly in 
sizes of nanoparticles. Particles had 158.38, 167.42, 170.56, 215.26 and 224.4 nanometres 
of average sizes respectively for the concentrations 1%, 2%, 3%, 4% and 5%. From Single 
Factor Analysis of Variance (ANOVA), P-value for the data of size was found to be 9.7x10-26.  
 Similarly, there was also difference between the zeta potentials of the nanoparticles 
whose stabilizer concentrations were the independent variable. The most negative value  
(-15.98mV) of zeta potential was that of the particles with 4% PVA whereas the molecules 
2%, 5%, 1% and 3% PVA concentrations followed with the average values of -13.74, -8.248, 
-6.51 and -6.31mV.  
 P-value for the data of zeta potential was calculated as 2.45x10-24 from Single Factor 
ANOVA. Since both P-values were smaller than α=0.05, the null hypothesis, "There isn't any 
significant difference between the biocompatibilities and drug delivery properties due to the 
different sizes and zeta potentials of nanoparticles that are prepared with 2% PLGA 
(poly(lactic-co-glycolic acid)) and varying concentrations (1%, 2%, 3%, 4% and 5%) of PVA 
(polyvinyl alcohol) by solvent evaporation method.", was rejected. 
 Although the data obtained from the experiment proved that there were significant 
differences between the characteristics of nanoparticles due to the concentrations of the 
chemicals used during the preparation, there were some error sources affecting the results. 
The biggest problem in the set-up was that the zeta potential values of samples were 
recorded one after another; some of the solutions had to wait until data of the previous 
concentrations were collected. It is known that aggregation and zeta potential of the 
molecules are affected of each other; values between +30mV and -30mV are accepted not to 
be stable. As the particles wait, they begin aggregating and their zeta potentials change. The 
zeta potentials were altered because of this time difference since aggregation happened 
during the wait. That's why; the data was not accurate especially for the concentrations 1% 
and 3% PVA. In order to reduce this error source, recordings can be done with separate 
devices simultaneously. However, this might introduce another random error source since 
the analyzer won't be identical for all of the samples. 
 Moreover, the organic phase was poured into the water phase with a syringe. Even 
though the addition was successful and at the same rate for all of the solutions in this 
experiment, it could have been different due to the hardness of pushing the syringe. Not only 
speed but also pressure variations might have occurred. For a more accurate experiment, it 
should be made sure that the syringes won't cause speed and pressure differences by being 
stuck. Syringes that can move easily should be preferred for better results. 
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 Finally, standard deviation and standard error values are shown in the following table 
for size data of the nanoparticles: 
For Size of Nanoparticle 
Concentration of 
PVA 
1% 2% 3% 4% 5% 
SD 0.609918 1.454991 1.422322 2.602499 0.353553 
SE 0.272764 0.650692 0.636082 1.163873 0.158114 
Table 5: shows standard deviation and standard error values for the data of size of nanoparticles with respect to 
their concentrations of PVA. 
 "Standard deviation shows how much variation exists from the average. A low 
standard deviation indicates that the data points tend to be very close to the mean."10 
whereas standard error is the standard deviation of the sample-mean estimate of a 
population mean.11 Standard deviation values are relatively low for 1% and 5% PVA 
concentrations yet that of the concentrations 2%, 3% and especially 4% are high. This 
situation can be explained with the variations caused by the addition with syringe. Uniform 
addition is important for the formation of similar sized nanoparticles. Thus, there is a 
systematic error in the experiment which results in inaccuracy and imprecision of size data. 
Besides, standard error value for 4% PVA concentration is also high, so that there must have 
been a mistake in the procedure for this solution. 
 For zeta potential data of the nanoparticles, standard deviation and standard error 
values are below: 
For Zeta Potential of Nanoparticle 
Concentration of 
PVA 1% 2% 3% 4% 5% 
SD 0.393128 0.230217 0.195959 0.294958 0.066858 
SE 0.175812 0.102956 0.087636 0.131909 0.0299 
Table 6: shows standard deviation and standard error values for the data of zeta potential of nanoparticles with 
respect to their concentrations of PVA. 
 Considering all of the standard deviation and standard error values are small, it can 
be concluded that data is precise and not spread out around the mean value for zeta 
potential.  
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Conclusion 
 My research question in this study was "How does changing the concentration of the 
stabilizer affect the surface properties of the nanoparticles and the drug delivery systems that 
are formed with the nanoparticles of 2% PLGA (poly(lactic-co-glycolic acid)) and the 
stabilizer concentrations of 1%, 2%, 3%, 4% and 5% PVA (polyvinyl alcohol), by solvent 
evaporation method?". After the experiment, it was observed that there are significant 
differences between the sizes and zeta potentials of nanoparticles that are produced with 
varying stabilizer concentrations. 
 The size values in this study were seen to be directly proportional to the 
concentrations whereas there were experimental errors affecting the accuracy of zeta 
potentials. However, the experimental data was still enough to show that there existed 
differences between the values. The method could be renewed to obtain more accurate 
results yet the overall experiment was successful. 
 This research provided experimental data to support that the surface properties of 
nanoparticles can be altered by changing their stabilizer concentrations. Nanotechnology is a 
very broad area investigating how characteristics of matter can be manipulated to have 
desired effects. I decided to narrow down my area of research by only experimenting on the 
effect of stabilizer concentration on size and zeta potentials of nanoparticles that are 
prepared by a specific method and with one constant polymer (PLGA). The study can be 
extended for larger research by changing the preparation method or the chemicals chosen 
for polymer, stabilizer and solvent. 
 In the light of this research, it can be said that it is possible to obtain molecules with 
sizes and zeta potentials that are advantageous in drug delivery systems. Only by changing 
the concentration of the stabilizer, various nanoparticle characteristics are attained. More can 
be achieved with different polymers and methods. For instance, the zeta potential can be 
used to have optimum permeability through membranes or size can be utilized for interaction 
with biological molecules of similar sizes. Therefore, better drug delivery systems can be 
built. The importance of this ability to manipulate matter at nano-scales is that diseases might 
be cured with less amount of drug, barriers in human body can be overcome and drug 
molecules can be kept in body for longer periods of time and for larger effects. As a 
conclusion, for bigger developments in medicine, nanotechnology offers great opportunities. 
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Appendices 
Appendix 1 
Below is the information about "solvent evaporation method" that was used to prepare 
nanoparticles of the polymer PLGA with stabilizer PVA. 
 In this method, the polymer is dissolved in an organic solvent such as 
dichloromethane, chloroform or ethyl acetate which is also used as the solvent for dissolving 
the hydrophobic drug. The mixture of polymer and drug solution is then emulsified in an 
aqueous solution containing a surfactant or emulsifying agent to form an oil in water (o/w) 
emulsion. After the formation of stable emulsion, the organic solvent is evaporated either by 
reducing the pressure or by continuous stirring. Particle size was found to be influenced by 
the type and concentrations of stabilizer, homogenizer speed and polymer concentration. In 
order to produce small particle size, often a high-speed homogenization or ultrasonication 
may be employed.2 
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Appendix 2 
Information about the device "Zetasizer", which was utilised in measuring size and zeta 
potential data, is given in the following pages. The principles of the machine are also 
included. 
A) Zetasizer Nano ZS 
Measurement type 1: 
Measurement type: Particle size and molecular size 
Measurement range: 0.3nm – 10.0 microns* (diameter). 
Measurement principle: Dynamic Light Scattering 
Minimum sample volume: 12µL 
Accuracy: Better than +/-2% on NIST traceable latex standards 
Precision/Repeatability: Better than +/-2% on NIST traceable latex standards 
 
Measurement type 2: 
Measurement type: Zeta potential (and optional Protein Mobility) 
Measurement range: 3.8nm – 100 microns (diameter)* 
Measurement principle: Electrophoretic Light Scattering 
Minimum sample volume: 150µL (20µL using diffusion barrier method) 
Accuracy: 0.12µm.cm/V.s for aqueous systems using NIST SRM1980 standard reference 
material 
Sensitivity: 10mg/mL (BSA). 
 
B) How size is measured using Dynamic Light Scattering? 
The principle of dynamic light scattering is that fine particles and molecules that are in 
constant random thermal motion, called Brownian motion, diffuse at a speed related to their 
size, smaller particles diffusing faster than larger particles. (...) To measure the diffusion 
speed, the speckle pattern produced by illuminating the particles with a laser is observed. 
The scattering intensity at a specific angle will fluctuate with time, and this is detected using a 
sensitive avalanche photodiode detector (APD). The intensity changes are analysed with a 
digital autocorrelator which generates a correlation function. This curve can be analysed to 
give the size and the size distribution. 
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C) How zeta potential is measured? 
The charge or zeta potential of particles and molecules is determined by measuring their 
velocity while they are moving due to electrophoresis. Particles and molecules that have a 
zeta potential will migrate towards an electrode if a field is applied. The speed they move is 
proportional to the field strength and their zeta potential. If we know the field strength, we 
simply measure the speed of movement, using laser Doppler electrophoresis, and then apply 
established theories to calculate the zeta potential. 
D) Why measurement of zeta potential is useful? 
The choices of materials used in a formulation may be restricted by regulations and also 
have an impact on cost. Knowledge of the zeta potential of particles in a formulation can be 
used to make logical choices about chemistry of a formulation in order to select the most 
appropriate materials to provide stability and improve shelf life. 
Zeta potential can also be used to study the effect of formulation components on other bulk 
properties such as viscosity, in order to achieve lower viscosity at higher concentrations for 
example.12 
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Appendix 3 
Information about the cenrifuge is listed below. 
Universal High Speed Centrifuges 
Z 383 / Z 383 K 
For High Speed Performance   
• Capacity for 4 x 500 ml at a speed of 5000 rpm 
• Accommodate nearly every size tube or bottle from 
  0.2 ml - 250 ml at high speeds 
• Spin many tubes at once (e.g. 48 x 15 ml) 
• Many rotors and adapters available for both swing-out 
  and fixed angle rotors as well as microplate rotors 
• High speed microrotors up to 17.000 rpm / 26.810 x g 
• High speed angle rotors for 85 ml or 50 ml up to 
  15.000 min-1 / 25.909 x g 
• Rotors are easy interchangeable13 
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Appendix 4 
Statistical formulas used during data analysis are written below. 
A) Arithmetic Mean 
The arithmetic mean of a set of values is the quantity commonly called "the" mean or the 
average. Given a set of samples , the arithmetic mean is14 
 
B) Median 
The word "median" has several different meanings in mathematics all related to the "middle" 
of mathematical objects. 
The statistical median is an order statistic that gives the "middle" value  of a sample. More 
specifically, it is the value  such that an equal number of samples are less than and greater 
than the value (for an odd sample size), or the average of the two central values (for an even 
sample size).15 
C) Mode 
The most common value obtained in a set of observations.16 
D) Standard Deviation 
The standard deviation  of a probability distribution is defined as the square root of 
the variance , 
  
 
  
 
where  is the mean,  is the second raw moment, and  denotes 
the expectation value of . The variance  is therefore equal to the second central 
moment (i.e., moment about the mean),17 
E) Standard Error 
The standard error of a sample of sample size  is the sample's standard deviation divided 
by . It therefore estimates the standard deviation of the sample mean based on 
the population mean. 
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The standard error of an estimate may also be defined as the square root of the estimated 
error variance  of the quantity,18 
 
F) Confidence Interval 
A confidence interval is an interval in which a measurement or trial falls corresponding to a 
given probability. Usually, the confidence interval of interest is symmetrically placed around 
the mean, so a 50% confidence interval for a symmetric probability density function would be 
the interval  such that19 
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Appendix 5 
Below are photographs of nanoparticles, having PVA concentrations of 1% and 3%, taken by 
Transmission Electron Microscopes (TEM) in METU, Ankara, Turkey. 
Image 1: shows a nanoparticle of 2%PLGA & 1%PVA. 
Image 2: shows nanoparticles of 2%PLGA & 1%PVA. 
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Image 4: shows nanoparticles of 2%PLGA & 1%PVA. 
Image 3: shows a nanoparticle of 2%PLGA & 1%PVA. 
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Image 5: shows nanoparticles of 2%PLGA & 1%PVA. 
Image 6: shows a nanoparticle of 2%PLGA & 3%PVA. 
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Image 7: shows a nanoparticle of 2%PLGA & 3%PVA. 
Image 8: shows nanoparticles of 2%PLGA & 3%PVA. 
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Image 9: shows a nanoparticle of 2%PLGA & 3%PVA. 
Image 10: shows nanoparticles of 2%PLGA & 3%PVA. 
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Image 11: shows nanoparticles of 2%PLGA & 3%PVA. 
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Appendix 6 
Following is the chemical structure of PLGA.
Image 12: shows chemical structure of PLGA molecule.20 
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Appendix 7 
Photographs below are taken by me during the preparation of nanoparticles in Hacettepe 
University, Ankara, Turkey.  
Image 13: shows nanoparticles of 2%PLGA & 1%PVA being stirred with magnetic stirrer. 
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Image 14: shows solutions containing nanoparticles of 2%PLGA & 1%PVA and 2%PLGA & 5%PVA. 
Image 15: shows solutions containing nanoparticles of 2%PLGA & 1%PVA and 2%PLGA & 5%PVA in centrifuge tubes. 
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